Found: 83
Select item for more details and to access through your institution.
Meeting report of the 6th Heidelberg Myeloma Workshop: current status and developments in diagnosis and therapy of multiple myeloma.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2017, v. 143, n. 12, p. 2521, doi. 10.1007/s00432-017-2463-x
- By:
- Publication type:
- Article
Patterns of progression in a contemporary cohort of 447 patients with smoldering multiple myeloma.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01159-8
- By:
- Publication type:
- Article
Longitudinal assessment of established risk stratification models in patients with monoclonal gammopathy of undetermined significance.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01126-3
- By:
- Publication type:
- Article
Extracellular vesicles mediate intercellular communication: Transfer of functionally active microRNAs by microvesicles into phagocytes.
- Published in:
- European Journal of Immunology, 2017, v. 47, n. 9, p. 1535, doi. 10.1002/eji.201646595
- By:
- Publication type:
- Article
Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial.
- Published in:
- Journal of Hematology & Oncology, 2019, v. 12, n. 1, p. N.PAG, doi. 10.1186/s13045-019-0750-5
- By:
- Publication type:
- Article
The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma.
- Published in:
- International Journal of Molecular Sciences, 2019, v. 20, n. 5, p. 1248, doi. 10.3390/ijms20051248
- By:
- Publication type:
- Article
Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single‐cell transcriptomics.
- Published in:
- Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-26951-z
- By:
- Publication type:
- Article
Whole‐body magnetic resonance imaging plus serological follow‐up for early identification of progression in smouldering myeloma patients to prevent development of end‐organ damage.
- Published in:
- British Journal of Haematology, 2022, v. 199, n. 1, p. 65, doi. 10.1111/bjh.18232
- By:
- Publication type:
- Article
Identification of patients with smouldering multiple myeloma at ultra‐high risk of progression using serum parameters: the Czech Myeloma Group model.
- Published in:
- British Journal of Haematology, 2020, v. 190, n. 2, p. 189, doi. 10.1111/bjh.16572
- By:
- Publication type:
- Article
Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma.
- Published in:
- British Journal of Haematology, 2019, v. 187, n. 4, p. 447, doi. 10.1111/bjh.16105
- By:
- Publication type:
- Article
Evolution of multiple myeloma treatment practices in Europe from 2014 to 2016.
- Published in:
- British Journal of Haematology, 2019, v. 185, n. 5, p. 981, doi. 10.1111/bjh.15680
- By:
- Publication type:
- Article
Multiple myeloma: patient outcomes in real-world practice.
- Published in:
- British Journal of Haematology, 2016, v. 175, n. 2, p. 252, doi. 10.1111/bjh.14213
- By:
- Publication type:
- Article
Multiple myeloma: practice patterns across Europe.
- Published in:
- British Journal of Haematology, 2016, v. 175, n. 1, p. 66, doi. 10.1111/bjh.14193
- By:
- Publication type:
- Article
Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG- HD2 trial.
- Published in:
- British Journal of Haematology, 2016, v. 173, n. 5, p. 731, doi. 10.1111/bjh.13994
- By:
- Publication type:
- Article
CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma - Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance.
- Published in:
- Frontiers in Immunology, 2018, p. 1, doi. 10.3389/fimmu.2018.01676
- By:
- Publication type:
- Article
The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma.
- Published in:
- 2016
- By:
- Publication type:
- journal article
IL-10 inducible CD8<sup>+</sup> regulatory T-cells are enriched in patients with multiple myeloma and impact the generation of antigen-specific T-cells.
- Published in:
- Cancer Immunology, Immunotherapy, 2018, v. 67, n. 11, p. 1695, doi. 10.1007/s00262-018-2230-0
- By:
- Publication type:
- Article
Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells.
- Published in:
- Oncogene, 2005, v. 24, n. 21, p. 3512, doi. 10.1038/sj.onc.1208536
- By:
- Publication type:
- Article
Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial.
- Published in:
- Cancers, 2023, v. 15, n. 18, p. 4667, doi. 10.3390/cancers15184667
- By:
- Publication type:
- Article
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma.
- Published in:
- Cancers, 2021, v. 13, n. 18, p. 4706, doi. 10.3390/cancers13184706
- By:
- Publication type:
- Article
Therapeutic Advances Propelled by Deciphering Tumor Biology and Immunology—Highlights of the 8th Heidelberg Myeloma Workshop.
- Published in:
- Cancers, 2021, v. 13, n. 16, p. 4135, doi. 10.3390/cancers13164135
- By:
- Publication type:
- Article
Pathway-Directed Therapy in Multiple Myeloma.
- Published in:
- Cancers, 2021, v. 13, n. 7, p. 1668, doi. 10.3390/cancers13071668
- By:
- Publication type:
- Article
Can 18F-NaF PET/CT before Autologous Stem Cell Transplantation Predict Survival in Multiple Myeloma?
- Published in:
- Cancers, 2020, v. 12, n. 5, p. 1335, doi. 10.3390/cancers12051335
- By:
- Publication type:
- Article
Potential therapeutic targets in plasma cell disorders: A flow cytometry study.
- Published in:
- Cytometry. Part B, 2017, v. 92, n. 2, p. 145, doi. 10.1002/cyto.b.21351
- By:
- Publication type:
- Article
Retrospective study on pomalidomide‐PACE as a salvage regimen in aggressive relapsed and refractory multiple myeloma.
- Published in:
- European Journal of Haematology, 2024, v. 113, n. 4, p. 465, doi. 10.1111/ejh.14254
- By:
- Publication type:
- Article
A precision‐based exercise program for patients with multiple myeloma.
- Published in:
- European Journal of Haematology, 2023, v. 111, n. 6, p. 930, doi. 10.1111/ejh.14106
- By:
- Publication type:
- Article
First‐line therapy with bendamustine/prednisone/bortezomib—A GMMG trial for non‐transplant eligible symptomatic multiple myeloma patients.
- Published in:
- European Journal of Haematology, 2020, v. 105, n. 2, p. 116, doi. 10.1111/ejh.13409
- By:
- Publication type:
- Article
Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials.
- Published in:
- BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-023-11507-9
- By:
- Publication type:
- Article
Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma.
- Published in:
- Transfusion Medicine & Hemotherapy, 2023, v. 50, n. 5, p. 371, doi. 10.1159/000529691
- By:
- Publication type:
- Article
Comparison of IGLV2‐14 light chain sequences of patients with AL amyloidosis or multiple myeloma.
- Published in:
- FEBS Journal, 2023, v. 290, n. 17, p. 4256, doi. 10.1111/febs.16805
- By:
- Publication type:
- Article
Analysis of long‐term survival in multiple myeloma after first‐line autologous stem cell transplantation: impact of clinical risk factors and sustained response.
- Published in:
- Cancer Medicine, 2018, v. 7, n. 2, p. 307, doi. 10.1002/cam4.1283
- By:
- Publication type:
- Article
Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the Prognosis.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.757664
- By:
- Publication type:
- Article
RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma.
- Published in:
- Frontiers in Immunology, 2023, p. 1, doi. 10.3389/fimmu.2023.1286700
- By:
- Publication type:
- Article
The prognostic significance of [<sup>18</sup>F]FDG PET/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs).
- Published in:
- EJNMMI Research, 2021, v. 11, n. 1, p. 1, doi. 10.1186/s13550-021-00846-y
- By:
- Publication type:
- Article
Understanding mortality in multiple myeloma: Findings of a European retrospective chart review.
- Published in:
- European Journal of Haematology, 2019, v. 103, n. 2, p. 107, doi. 10.1111/ejh.13264
- By:
- Publication type:
- Article
The immunoglobulin superfamily ligand B7H6 subjects T cell responses to NK cell surveillance.
- Published in:
- Science Immunology, 2024, v. 9, n. 95, p. 1, doi. 10.1126/sciimmunol.adj7970
- By:
- Publication type:
- Article
Expression of Mucin-1 in multiple myeloma and its precursors: correlation with glycosylation and subcellular localization.
- Published in:
- Histopathology, 2014, v. 64, n. 6, p. 799, doi. 10.1111/his.12330
- By:
- Publication type:
- Article
Cobimetinib Alone and Plus Venetoclax With/Without Atezolizumab in Patients With Relapsed/Refractory Multiple Myeloma.
- Published in:
- 2023
- By:
- Publication type:
- journal article
P-193: Elotuzumab plus pomalidomide/dexamethasone for relapsed/refractory multiple myeloma: final overall survival from the phase 2 ELOQUENT-3 trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S143, doi. 10.1016/S2152-2650(21)02320-X
- By:
- Publication type:
- Article
P-188: Carfilzomib, lenalidomide, and dexamethasone followed by salvage autologous stem cell transplant with or without maintenance for relapsed or refractory multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S140, doi. 10.1016/S2152-2650(21)02315-6
- By:
- Publication type:
- Article
P-177: Predictive factors for severe infections and early death during novel agent-based induction therapy in newly diagnosed, transplant-eligible myeloma: a multicohort analysis from phase III trials.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S133, doi. 10.1016/S2152-2650(21)02304-1
- By:
- Publication type:
- Article
P-138: Frequent magnetic resonance imaging partially reduces the development of end organ damage in patients with smoldering myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S110, doi. 10.1016/S2152-2650(21)02265-5
- By:
- Publication type:
- Article
P-060: Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single cell transcriptomics.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S71, doi. 10.1016/S2152-2650(21)02194-7
- By:
- Publication type:
- Article
P-049: The spatial sub-clonal architecture in newly diagnosed myeloma patients revealed by whole genome and single-cell sequencing.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S65, doi. 10.1016/S2152-2650(21)02183-2
- By:
- Publication type:
- Article
OAB-023: Efficacy and safety of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with progressive multiple myeloma after 1–3 prior lines of therapy: Initial results from CARTITUDE-2.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S15, doi. 10.1016/S2152-2650(21)02097-8
- By:
- Publication type:
- Article
OAB-007: Single-cell multiomic analysis identifies regulatory programs in relapsed/refractory multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S5, doi. 10.1016/S2152-2650(21)02081-4
- By:
- Publication type:
- Article
Impact of cytogenetics at relapse on prognosis and benefit from salvage autologous stem cell transplantation in the GMMG phase III trial ReLApsE.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e286, doi. 10.1016/j.clml.2019.09.471
- By:
- Publication type:
- Article
Elotuzumab, Pomalidomide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Efficacy After Additional Follow-Up of the ELOQUENT-3 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e164, doi. 10.1016/j.clml.2019.09.275
- By:
- Publication type:
- Article
The mutational landscape underlying carfilzomib and pomalidomide resistance in relapsed /refractory multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e83, doi. 10.1016/j.clml.2019.09.133
- By:
- Publication type:
- Article